Dear colleagues, friends, and supporters: As we approach 2024, we want to take a moment to look back over an absolutely astounding year of progress for our business and give thanks to the many who made it possible. Nearly a decade of hard work culminated in an industry-first achievement here at Antheia. In August, we […]
Antheia’s Chief Operations Officer Zack McGahey offers his perspective on the company’s most recent commercial milestone – a successful full-scale fermentation run of its first product at 116,000L.
Sherwin to lead Antheia’s global sales strategy for KSM and API products Menlo Park, CA – August 17, 2023 – Antheia, the pharmaceutical ingredient manufacturer transforming essential medicine supply chains, today announced the appointment of industry veteran, Richard Sherwin as SVP of Commercialization. Sherwin’s hiring comes at a critical juncture in Antheia’s growth trajectory as […]
Since launching Antheia in 2015, we’ve made tremendous strides toward our mission to transform pharmaceutical supply chains for essential medicines. We’ve strengthened our leadership team with veteran executives across R&D, operations, supply chain, and quality and regulatory, we’ve repeatedly validated our technology at commercially-relevant scales, and we are now actively moving into full-scale production to bring our products to market.
Antheia, the pharmaceutical ingredient manufacturer transforming supply chains, today announced the appointment of John Nicols to Chair its Board of Directors. Nicols joins co-founders Dr. Christina Smolke (CEO) and Dr. Kristy Hawkins (CSO), as well as Ram Shriram and Dr. Patrick Yang on the Antheia Board of Directors.
This year has been ripe with growth, major achievements, and opportunities to showcase who and what make Antheia the visionary business it is. Nearly eight years ago, we co-founded Antheia…
Antheia, a synthetic biology company enabling next-generation plant-inspired medicines, today announced $40 million in venture debt financing from Oxford Finance LLC and Silicon Valley Bank, alongside plans to construct a new pilot scale biomanufacturing facility.
While some synthetic biology companies are using biology to improve our food, clothes, and medicine, others are turning their attention to helping the Earth.
Fundraising at Bota Bio, Genomatica, and Antheia signals an upshift for commercial-scale synthetic biology…
Antheia, a Menlo Park CA-based synthetic biology company, raised $73M in Series B funding. The round was led by Viking Global Investors with participation from Sherpalo Ventures and Hillspire…